

APAC Scientific Forum

March 7, 2024



Agenda

- STEMI Network Study Introduction by Atif Adam
- Perseus Introduction and Demonstration by Anton Ivanov



ST-elevation myocardial infarction (STEMI)

Network Study

Dr Mirza Khan Fellow in Cardiovascular Outcomes Research, University of Missouri-Kansas City, Saint Luke's Mid America Heart Institute Milou Brand Senior Data Scientist, OMOP, IQVIA Atif Adam Associate Director of Epidemiology, OMOP, IQVIA

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.


Background

ST-elevation myocardial infarction (STEMI)

- In 2019, an estimated 17.9 million people died from CVDs, which is 32% of all global deaths. Of these deaths, 85% are due to acute myocardial infarction (AMI)
- In United States alone, 1 American will suffer an AMI every 40 secs: estimated annual incidences of new and recurrent MI events are 550,000 and 200,000 events, respectively (1).

In the 4th Universal Definition of Myocardial Infarction (UDMI) defines acute ST-elevation myocardial infarction (STEMI) requires:

- a rise and/or fall of cardiac troponin (cTn) values and clinical evidence of ischemia (i.e., symptoms, ECG changes, supportive ECG or other imaging findings, or evidence of coronary thrombus). The underlying etiology is plaque disruption with coronary atherothrombosis (2, 3, 4).
 - > Acute STEMI can manifest as:
 - » hyperacute T-wave changes
 - » true posterior MI
 - » multi-lead ST depression with coexistent ST elevation in lead aVR
 - » characteristic diagnostic criteria in the setting of left bundle branch block





⁽¹⁾ Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016; 133:e38-360.

⁽²⁾ Asatryan B, Vaisnora L, Manavifar N. Electrocardiographic Diagnosis of Life-Threatening STEMI Equivalents. JACC: Case Reports. 2019;1(4):666-668. doi:10.1016/j.jaccas.2019.10.030

⁽³⁾ Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022). Acute coronary syndromes. The Lancet, 399(10332), 1347–1358. https://doi.org/10.1016/S0140-6736(21)02391-6

⁽⁴⁾ Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20). doi:10.1161/cir.0000000000000017

Rationale

Acute STEMI characterization and incidence rates


Given the acuity and "need for speed" in treating acute STEMI cases, accurate and scalable generalizable identification, characterization, and current incidence of STEMI in multi-country real-world data has many benefits.

For example, informing on resource allocation, campaigns to improve heart attack recognition, cardiovascular health, and risk factor modification, etc.

This comprehensive study aims to understand STEMI patients' characteristics and identify the incidence rates across multiple real-world data datasets.

Research questions:

- To understand the patients' characteristics of acute STEMI patients
- To understand incidence rates of acute STEMI patients






Study design

- **Design**: This will be a retrospective cohort study of patients diagnosed with acute STEMI.
- <u>Data sources</u> can be administrative claims, registry, or electronic health records (EHR) data mapped to the OMOP CDM across the OHDSI network.
- <u>The primary study population</u> will consist of adult patients with an acute STEMI diagnosis identified in the data sources.
- <u>The overall study period</u> will span from January 1, 2016, up to the most recent data available for the given data sources.



Outline of cohort design

Acute STEMI





7

Data analysis

Strategus

- The package uses the OHDSI Strategus framework for execution, previously been used for HowOften and SOS Challenge within the OHDSI community.
- The Strategus package includes the CohortDiagnostics module:
 - To identify features and calculate the incidence rates of patients in the STEMI cohort.
 - Features will be extracted from the 365-day observation prior to cohort entry and will include variables such as demographic data (sex, age group, race, ethnicity), prior conditions, drug exposures, procedures, measurements, observations, and risk scores (e.g., Charlson comorbidity index, DCSI, CHADS2VASC score).
 - Incidence rates will be calculated for the STEMI cohort. The rate is calculated the number of new STEMI cases per 1,000 person-years (PY) of the total patients at risk of getting exposed each calendar year.




Preliminary timelines

Spread the word

If you are interested to join, please let us know!

https://forums.ohdsi.org/t/join-our-cvd-ohdsi-network-study-on-acute-stemi/21258





9

Thanks, any questions?





"Perseus": Design and run your own ETL to CDM



Perseus Anton Ivanov, MS¹, Samus Sergey, MS¹, Alexander Efimov, MS¹, Maxim Draschinsky, MS¹, Dolotova Maria, MS¹, Matvey Chudakov, MS¹, Karpushina Anna, MS¹, Semenov Artem, MS¹

¹Arcadia Inc., St. Petersburg, Russia

Background

There are several opensource ETL tools designed for CDM and available for OHDSI community. Tools for code mapping and quality control provide a good starting point to design ETL process for getting CDM but ETL implementation still requires technical skills in programming languages and platforms. Presented solution addresses this need and provides a visual designer for ETL implementation targeting CDM.

Methods

"Perseus" is combination of Web application for ETL configuration and engine for: conversion of native data into CDM, data quality check, code mapping, generating ETL document and vocabulary search.



Source tables (23) 0.544 E PAT2

> **ADDITIONAL** BATCHNUMBER # BNFCODES E CLINICAL

E COMMONDOSAGES

I DAYSUPPLY_DECODES

CONSULTATION

"Perseus" has instruments for all major steps of creating an ETL.

Step 1: Scan source data

Scan Data	× Po	 Use White Rabbit scan report or scan the source data directly 						
Source Data Location Data too CSV files	Tables to Scan Q, Search by Tables Telect All Develoct All		Source	columns (12	(4)		Source tab	
sisct files rug.csv. inpatient.csv. patient.csv	🗹 drug.cav		Q, Sea	rch by source			Q, Search	
Indur	inpatient.csv		Selected: 0				Create View	
Clear of	patient.csv		- k <	PATIENT	STAFF		≡ PAT2	
			h. E	IL E Field name: gender			E ADDI	
		i. / Field type: smallint Unique values: 10				E BATC		
			- h. E	Value	Frequency	Percentage	# BNFC	
Test Connection			1. E	2	52048	0.24739	E CLIN	
✓ Carriedad			1. E	1	47934	0.22874	E COM	
Þ			_	3	5934	0.11854		
Cancel	Scan Tables		h. C	4	3434	0.10345	E CONS	
		_	1. E	0	2351	0.01234	E DAYS	



Step 2: Create the Code Mappings

1	COM ETL	Import codes + Mapping								Input han - ICPC25NOMED.cov		
Source						Target	rget					
E	Beurse Colle	Bourse Term	Pequency	Duty Term	Match Boorn	Concept ID	Concept Name	Durrate	Concept Dass	Teachulary	Concept Code	Standart Co.
	A89.00	General Droeace	6774012	Somorameter	1.79	435569	Sunename	Condition	Clinical Fin	SNOHED	435509	8
E	K86.00	Hypertension	3067206	Somerameter	8.72	✓ 42700687	Somename	Condition	Clinical Fin	SNOHED	42720887	8
	844.00	Cough	3790006	Someramdrer	841	4102787	Sonenane	Condition	Clinical Fin	INDUED	4102757	8
	T99.02	Upper respic	1290874	Somerameter	8.91	201626	Somename	Condition	Cinical Fin	SACHED	201826	8
	R05-00	General sympt	9912705	Somenameher	6.58	1480000	Sonesane	Condition	Cinical Fin.,	SNOHED	1488202	8
	RN-00	Lowback symp	1098347	Somonamicher	1.00	34890723	Somename	Condition	Cinical Fin	SNOHED	04894728	5
	A28.00	Hypertension	4589023	Somerameher	8.67	42709887	Somename	Condition	Cinical Fin.	SNORED	42729807	5
	L03.00	Upper mepic	7612297	Somerameter	6.03	201826	Somename	Condition	Clinical Fin	SNOHED	201826	5
	LI71.00	General sympt	2039616	Somerameter	8.04	4102757	Sunerane	Condition	Cinical Fin	SNOHED	4102757	9
	T00.02	Upper rengin	1290874	Sunoramdrer	6.72	42709887	Somename	Condition	Cinical Fin	SNORED	42729887	8
	805.00	General sympt	8912788	Sunoramber.	0.41	4102757	Sonesane	Condition	Cinical Fin.,	SNONED	4102757	8
	B74.00	Low back symp	1098347	Somonamelier	8.01	201826	Somename	Condition	Clinical Fin	SNOHED	201826	8
	A28-00	Hypertension	4589000	Somenamelier	6.58	1480000	Somename	Condition	Cinical Fin.,	SNOHED	1483202	8

Concept Configs FIEL21 1.0003P 1 Select Lookup (ii) Some Cancel Acoly

Step 3: Design and run ETL



- ✓ Visually map raw data to CDM
- Embedded set of transformations
- Embedded set of lookups
- ✓ Combine source tables
- Combine fields into groups
- Configure conditional mappings
- ✓ Automatic era creation
- Automatic domain switching

Step 4: Quality Control



Integrated Data Quality Dashboard

Conclusions

"Perseus" reduces the time spent on manual processes such as writing code and mapping source data to target systems. The configuring and running ETLs with "Perseus" makes it repeatable, shareable and saves time.

References:

10

- 1. Perseus https://github.com/SoftwareCountry/Perseus 2. White Rabbit, and Rabbit-in-a-Hat https://github.com/SoftwareCountry/WhiteRabbit
- 3. Usagi https://github.com/OHDSI/Usagi
- 4. Achilles https://github.com/OHDSI/Achilles
- 5. DQD https://github.com/SoftwareCountry/DataQualityDashboard
- 6. CDM Builder https://github.com/SoftwareCountry/ETL-CDMBuilder



Thank you!